Amarin Corp Plcuk (AMRN) Long-Term Investments (2020 - 2023)
Amarin Corp Plcuk (AMRN) reported Long-Term Investments of $100000.0 for Q2 2023, down 99.12% year-over-year from $11.4 million in Q2 2022, and down 81.62% quarter-over-quarter from $544000.0 in Q1 2023.
Amarin Corp Plcuk (AMRN) Long-Term Investments (2020 - 2023) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 4 years of Long-Term Investments data on file, last reported at $100000.0 in Q2 2023.
- Long-Term Investments for Q2 2023 came in at $100000.0, down 99.12% year-over-year; the trailing twelve-month figure through Jun 2023 was $100000.0 (down 99.12% YoY), and the FY2022 annual result was $1.3 million, down 96.36% from the prior year.
- Long-Term Investments declined to $100000.0 in Q2 2023 per AMRN's latest filing, from $544000.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $81.5 million in Q1 2020 and troughed at $100000.0 in Q2 2023.
- A 4-year average of $29.0 million and a median of $25.4 million in 2021 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments rose 11.24% in 2022, then slumped 99.12% in 2023.
- A 4-year view of Long-Term Investments shows it stood at $62.5 million in 2020, then sank by 43.98% to $35.0 million in 2021, then plunged by 96.36% to $1.3 million in 2022, then plunged by 92.16% to $100000.0 in 2023.
- Business Quant data shows AMRN's Long-Term Investments at $100000.0 in Q2 2023, $544000.0 in Q1 2023, and $1.3 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 133.47 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 3.12 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 268.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 983.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 1.63 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 366.00 Mn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 544,000.00 |
| Dec 31, 2022 | 1.28 Mn |
| Sep 30, 2022 | 2.30 Mn |
| Jun 30, 2022 | 11.40 Mn |
| Mar 31, 2022 | 26.70 Mn |
| Dec 31, 2021 | 35.00 Mn |
| Sep 30, 2021 | 38.80 Mn |
| Jun 30, 2021 | 14.16 Mn |
| Mar 31, 2021 | 24.00 Mn |
| Dec 31, 2020 | 62.47 Mn |
| Sep 30, 2020 | 46.09 Mn |
| Jun 30, 2020 | 61.04 Mn |
| Mar 31, 2020 | 81.50 Mn |